that FDA voucher thingy
..i don't believe they are called "coupons" and any biotech CEO should actually know better..
..i know two recent cases where the vouchers went for $245 to $300M US
..i haven't quite figured out yet what say company X gets voucher sells to company Y and early trial fails..it is an odd system for sure. i beieve it is meant to mitigate financial risk for drug development in very special cases (pediatric, ebola, etc.) with special market dynamics but it seems like the FDA gifting economic benefits...odd for sure but i suspect one of those will likely double the market cap of RVX